| Value | ₹550.0 Cr |
|---|
BSE filing, NSE: BLACKBUCK. Summary written from the filing by ALFA Finder's alert engine.
Black Buck Ltd: key numbers
- Share price
- ₹564.00
- Market cap
- ₹10,278 Cr
- Revenue (annual)
- ₹652.0 Cr
- Net profit (annual)
- ₹160.3 Cr
- P/E (TTM)
- 56.8×Sector 27.7×
- Promoter holding
- 24.99%-0.01% QoQ
- FII holding
- 31.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Black Buck Ltd
All →Black Buck Earnings Call Transcript: Key Takeaways
Black Buck delivered strong 51% revenue growth, fueled by aggressive customer acquisition and new initiatives.
Black Buck Employee Stock Options
BlackBuck granted 34,399 stock options under its ESOP 2016 scheme at ₹1 per share. Options vest at 25% per year over four years with no lock-in.
Black Buck Debt & Borrowing: ₹40 Cr
BlackBuck's board approved a ₹40 Crore corporate guarantee to Axis Bank securing a term loan for subsidiary Blackbuck Finserve. No immediate financial impact on the company.
- Value
- ₹40.00 Cr
BlackBuck Management Change
BlackBuck redesignated Mr. Abhishek Singh as Chief Business Officer, effective October 29, 2026. This internal senior management restructuring carries no financial impact.
Black Buck Other Announcement
BlackBuck's ICRA monitoring agency report for Q1 FY27 confirms IPO proceeds utilization remains in line with stated objects. No deviation was observed in the quarter.
BlackBuck Investor Presentation: Key Takeaways
Q2FY27 total income ₹253.15 Cr (+51% YoY), revenue from operations ₹235.33 Cr (+56%), PAT ₹41.40 Cr (+42%). Growth led by tolling, telematics and Superloads.
Other fund raise announcements
All →Rite Zone Chemcon India Fund Raise of ₹6.58 Cr
Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.
- Value
- ₹6.58 Cr
Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.